By Ahmed Aboulenein WASHINGTON, Feb 23 (Reuters) - U.S. Food and Drug Administration Commissioner Marty Makary on Monday ...

The Food and Drug Administration (FDA) has backtracked its initial decision last week of refusing to review Moderna’s mRNA ...

Commissioner Marty Makary defended his agency's position and record on mRNA vaccines, days after it changed course and agreed ...

Moderna announced that the FDA agreed to review its application for a mRNA-based flu vaccine after it agreed to further study in older adults.

In a sudden reversal, the US Food and Drug Administration has agreed to review Moderna’s experimental mRNA influenza vaccine.

Two weeks ago, the FDA took the rare step of refusing to accept Moderna’s application for its first mRNA flu vaccine. After ...

Moderna announced that the FDA will review its new mRNA flu vaccine, a reversal less than two weeks after the agency refused ...

After initially rejecting Moderna’s application for review, the FDA will now consider the company’s mRNA flu shot ...

Moderna said it met with the FDA on Tuesday to discuss the vaccine and afterward, the U.S. regulator accepted a revised ...

In an experimental trial, a personalized mRNA vaccine was tested in 14 individuals with an aggressive form of breast cancer. It trained immune cells to target cancer-specific mutant proteins, inducing ...

Arbutus alleges that Moderna’s COVID-19 vaccine infringes on patents protecting its lipid nanoparticle delivery technology.

The U.S. Food and Drug Administration announced recently that it will not review Moderna’s mRNA flu vaccine, despite late-stage trials showing it was safe and effective. The rejection has many in and ...